Breast Tumor Ablation Study Parameters To Be Reviewed By FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Clinical trial criteria for studying percutaneous breast tumor removal devices will be explored by FDA's General & Plastic Surgery Devices Panel during a July 24 meeting in Gaithersburg, Md
You may also be interested in...
Hemostatic Agent Downclassification Should Await Guidance – Panel
FDA plans to develop a draft guidance document for absorbable hemostatic agent 510(k) submissions and submit it for panel review before reconsidering downclassification of the devices
Endocare Gains Clearance For Benign Breast Tumor Therapy; Malignant Next
Endocare will follow up its FDA 510(k) clearance of the Visica minimally invasive cryoablation system for benign breast tumors with a submission for malignant tumors.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.